Coronavirus (COVID-19)
- Dexamethasone in COVID-19 treatment: Analyzing monotherapy and combination therapy approaches
- Efficacy of tocilizumab for hospitalized patients with COVID-19 pneumonia and high IL-6 levels: A randomized controlled trial
- Tocilizumab, sarilumab and anakinra in critically ill patients with COVID-19
- Long-term functional prognosis with tocilizumab in severe COVID-19 infection: A study on mechanically ventilated ICU patients
- Molnupiravir Use Among Patients with COVID-19 in Real-World Settings: A Systematic Literature Review
- US Real-World Effectiveness Study of Nirmatrelvir/Ritonavir in Preventing Hospitalization of High-Risk COVID-19 Patients
- Effectiveness of molnupiravir as early treatment for COVID-19 to prevent mortality and hospitalisation in high-risk adults
- Molnupiravir or nirmatrelvir–ritonavir plus usual care versus usual care alone in patients admitted to hospital with COVID-19 (RECOVERY)
- Ritonavir-Boosted Nirmatrelvir Prescribing Information
- The Burden of COVID-19 in the Immunocompromised Patient: Implications for Vaccination and Needs for the Future
- Vaccines and therapeutics for immunocompromised patients with COVID-19
- Impact of COVID-19 on immunocompromised populations during the Omicron era: insights from the observational population-based INFORM study
- The Evolving Role of the Rheumatology Practitioner in the Care of Immunocompromised Patients in the COVID-19 Era
- Long COVID: major findings, mechanisms and recommendations
- CDC: COVID-19 Vaccines for People Who Are Moderately or Severely Immunocompromised
- IDSA and CDC COVID-19 Real-Time Learning Network: Immunocompromised Populations
- COVID-19 Drug Interactions
- IDSA Guidelines on the Treatment and Management of Patients with COVID-19
- Efficacy and safety of baricitinib plus standard of care for the treatment of critically ill hospitalized adults with COVID-19 on invasive mechanical ventilation or extracorporeal membrane oxygenation
- NIH COVID-19 Treatment Guidelines
- FDA COVID-19 Emergency Use Authorizations: Drug and Biological Therapeutic Products
- Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19 (ACTT-2)
- Efficacy and safety of baricitinib for the treatment of hospitalized adults with COVID-19 (COV-BARRIER)
- Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19: A Meta-analysis
- CDC Coronavirus Disease 2019 (COVID-19) Resources
- WHO Resources: COVID-19 Pandemic
- JAMA Patient Page: Oral antiviral medications for COVID-19
- Molnupiravir EUA
- Nirmatrelvir EUA
Cytomegalovirus (CMV)
- Consensus Guidelines on the Management of Cytomegalovirus in Solid-organ Transplantation
- About CMV For Patients
- Letermovir for Prevention of Recurrent Cytomegalovirus in High-Risk Allogeneic Hematopoietic Cell Transplantation Recipients
- Letermovir as secondary prophylaxis of cytomegalovirus infection after allogeneic hematopoietic cell transplantation
- Real-world experience with letermovir for cytomegalovirus-prophylaxis after allogeneic hematopoietic cell transplantation: A multi-centre observational study
- Letermovir for Secondary Prophylaxis of CMV Infection
- Cytomegalovirus (CMV) Infection
- Clinical manifestations, diagnosis, and management of CMV disease in kidney transplant recipients
Gram-Negative Bacterial Infections
- Innovative Antibiotic Therapies for Carbapenem-Resistant Gram-Negative Bacterial Infections: Clinical Efficacy, Safety, and Comparative Studies
- Clinical efficacy of cefiderocol-based regimens in patients with carbapenem-resistant Acinetobacter baumannii infections: New data from CREDIBLE-CR
- Gram-negative Bacteria Infections in Healthcare Settings
- IDSA Guidance on the Treatment of Antimicrobial-Resistant Gram-Negative Infections: Version 1.0
- Cefiderocol versus high-dose, extended-infusion meropenem for the treatment of Gram-negative nosocomial pneumonia (APEKS-NP): a randomised, double-blind, phase 3, non-inferiority trial
Herpes Zoster
HIV
- HIV Compendium of Best Practices
- Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents with HIV
- INSTI Drug Interactions
- HIV and Drug-resistance Testing
- Optimizing Antiretroviral Therapy in the Setting of Virologic Suppression
- Adherence to the Continuum of Care
- Drug-Drug Interactions
- Drug Database: Cabotegravir
- Women with HIV
- Adverse Effects of Antiretroviral Therapy
- Considerations for Antiretroviral Therapy in the Older Patient
- Stanford University HIV Drug Resistance Database
- Understanding HIV Laboratory Tests – for Patients
- NNRTI Drug Interactions
- NRTI Drug Interactions
- PI Drug Interactions
- Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents- Tables
- What to Start: Selecting a First HIV Regimen
PrEP
- Drug Information on Lenacapavir
- Twice-Yearly Lenacapavir or Daily F/TAF for HIV Prevention in Cisgender Women
- Twice-Yearly Lenacapavir for HIV Prevention in Men and Gender-Diverse Persons
- CDC: PrEP Guidelines – 2021 Update
- Patient/Clinician Handout: PrEP 2-1-1
- HIV PrEP With FTC/TDF Among Cisgender Women
- Equity of Prep Uptake by Race, Ethnicity, Sex, and Region in the US in the First Decade of Prep
- Characteristics Associated with PrEP Discussion and Use Among Transgender Women Without HIV Infection – National HIV Behavioral Surveillance
- Postexposure Doxycycline to Prevent Bacterial Sexually Transmitted Infections
- Safety Review of TDF/FTC PrEP for Pregnant Women at Risk of HIV Infection
- PrEP Resources in all 50 States
- National Clinician Consultation Center for PrEP
- Preexposure Prophylaxis for the Prevention of HIV Infection of the United States – 2021 Update
- Quick Guide: 2021 PrEP Update
- HIV Prevention Materials for Your Practice
- Let’s Stop HIV Together: HIV Prevention
- Drug information on cabotegravir
- Cabotegravir for HIV Prevention in Cisgender Men and Transgender Women (HPTN 083)
- Long acting injectable cabotegravir is safe and effective in preventing HIV infection in cisgender women: results from HPTN 084
Influenza
- Comparative Effectiveness of Cell-Based Versus Egg-Based Influenza Vaccines in Prevention of Influenza Hospitalization During the 2022–2023 Season Among Adults 18–64 Years
- Efficacy of Baloxavir Treatment in Preventing Transmission of Influenza
- FDA-cleared Nucleic Acid Detection Based Tests for Influenza Viruses
- What You Should Know About Influenza (Flu) Antiviral Drugs
- Similarities and Differences between Flu and COVID-19
- A Phase 3 Safety and Efficacy Study of Baloxavir Marboxil in Children Less Than 1 Year Old With Suspected or Confirmed Influenza
- Population Pharmacokinetic and Exposure-Efficacy Analysis of Baloxavir Marboxil for Influenza Treatment and Post-Exposure Prophylaxis in Children
- Influenza Antiviral Drug Resistance
- Influenza vaccines: the potential benefits of cell-culture isolation and manufacturing
- Baloxavir Marboxil for Prophylaxis against Influenza in Household Contacts
- Seasonal Influenza Vaccine Effectiveness Studies
- Influenza Antiviral Medications: Summary for Clinicians
- Information for Clinicians on Influenza Virus Testing
- People at High Risk For Flu Complications
- Baloxavir Marboxil Single-dose Treatment in Influenza-infected Children
- Early Treatment With Baloxavir Marboxil in High-Risk Adolescent and Adult Outpatients With Uncomplicated Influenza (CAPSTONE-2): A Randomised, Placebo-controlled, Phase 3 Trial
Invasive Fungal Infections
- CDC Fungal Diseases – Patient Information
- Information for Healthcare Professionals about Invasive Candidiasis
- Information for Healthcare Professionals about Mucormycosis
- Information for Healthcare Professionals about Aspergillosis
Molecular Diagnostics
- European society of clinical microbiology and infectious diseases guidelines for antimicrobial stewardship in emergency departments
- The role of rapid multiplex molecular syndromic panels in the clinical management of infections in critically ill patients: an experts-opinion document
- Clinical and cost implications of Biofire FilmArray® meningitis / encephalitis panel testing
- Performance of the BIOFIRE® Filmarray Pneumonia Plus Panel for quantifiable bacterial targets compared to semiquantitative culture methods
Pediatrics
Pneumococcal Disease
- Pneumococcal Disease
- Advisory Committee on Immunization Practices (ACIP): Pneumococcal Vaccine Recommendations
- Updated ACIP Recommendations and Evidence Review: Use of 15-Valent Pneumococcal Conjugate Vaccine Among U.S. Children
- Immunize.org Ask the Experts: Pneumococcal Vaccines for Children and Adults
- Pneumococcal Conjugate Vaccine Breakthrough Infections: 2001-2016
- PneumoRecs VaxAdvisor Mobile App
- Marked Reduction of Socioeconomic and Racial Disparities in Invasive Pneumococcal Disease Associated With Conjugate Pneumococcal Vaccines
- PCV15 Prescribing Information
- PCV20 Prescribing Information
Respiratory Syncytial Virus (RSV)
- Safety, Immunogenicity, and Regimen Selection of Ad26.RSV.preF-Based Vaccine Combinations: A Randomized, Double-blind, Placebo-Controlled, Phase 1/2a Study
- Efficacy of Respiratory Syncytial Virus Vaccination to Prevent Lower Respiratory Tract Illness in Older Adults
- Burden of Respiratory Syncytial Virus–Associated Hospitalizations in US Adults, October 2016 to September 2023
- RSV Prefusion F Vaccine for Prevention of Hospitalization in Older Adults
- CYPRESS Phase 2b Data on the Efficacy and Immunogenicity of an Ad26.RSV.preF-based RSV Vaccine
- Incidence of Respiratory Syncytial Virus Infection Among Hospitalized Adults, 2017-2020
- Respiratory Syncytial Virus (RSV)
- CDC Factsheet. RSV in Older Adults and Adults with Chronic Medical Conditions
- Respiratory Syncytial Virus Infection
